Recombinant Methionyl Human Leptin Therapy in Replacement Doses Improves Insulin Resistance and Metabolic Profile in Patients with Lipoatrophy and Metabolic Syndrome Induced by the Highly Active Antiretroviral Therapy | Zendy

Jennifer H. Lee | Zendy; Jean L. Chan | Zendy; Epamidas Sourlas | Zendy; Vassilios Raptopoulos | Zendy; Christos S. Mantzoros | Zendy

Open Access

Recombinant Methionyl Human Leptin Therapy in Replacement Doses Improves Insulin Resistance and Metabolic Profile in Patients with Lipoatrophy and Metabolic Syndrome Induced by the Highly Active Antiretroviral Therapy

Author(s) -

Jennifer H. Lee,

Jean L. Chan,

Epamidas Sourlas,

Vassilios Raptopoulos,

Christos S. Mantzoros

Publication year - 2006

Publication title -

the journal of clinical endocrinology and metabolism

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.206

H-Index - 353

eISSN - 1945-7197

pISSN - 0021-972X

DOI - 10.1210/jc.2005-1545

Subject(s) - lipoatrophy , lipodystrophy , insulin resistance , medicine , endocrinology , leptin , insulin , metabolic syndrome , triglyceride , homeostatic model assessment , glucose homeostasis , lipid profile , diabetes mellitus , cholesterol , obesity , viral load , immunology , antiretroviral therapy , human immunodeficiency virus (hiv)

Highly active antiretroviral therapy (HAART) for HIV-1 infection has been associated with a metabolic syndrome characterized by insulin resistance, hyperlipidemia, and redistribution of body fat (lipodystrophy). A subset of patients with predominant lipoatrophy has low levels of the adipocyte-secreted hormone leptin.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research